{"entity":{"id":"nct07635290","kind":"trial","name":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer","aka":[],"tldr":"A phase 2 trial of cadonilimab and anlotinib in gallbladder cancer and other biliary tract cancers, run by West China Hospital, active and no longer recruiting.","summary":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT07635290 by West China Hospital, with a registry enrolment figure of 26 participants, started 2026-06-03 and due to reach its primary completion in 2027-06-30. Interventions recorded: Anlotinib + Cadonilimab, PULSAR. Conditions listed: Previously Treated, Advanced, Biliary Tract Cancers. Sites: China. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07635290","url":"https://clinicaltrials.gov/study/NCT07635290"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":["bispecific-antibody","checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["cadonilimab","anlotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07635290","phase":"2","setting":"A Phase II Clinical Trial of Anlotinib Combined With Cadonilimab and PULSAR in Previously Treated Advanced Unresectable or Metastatic Biliary Tract Cancer","sponsor":"West China Hospital","enrolled":26,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07635290/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"},{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}